Tag: cybersecurity

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

The global military unmanned underwater vehicles market, valued at $3.94 billion in 2024, is projected to grow at a 7.93% CAGR to $8.26 billion by 2034. Key drivers include military modernization and government initiatives. North America leads, while Asia-Pacific is the fastest-growing region. Against cybersecurity risks and high costs, electric and autonomous vehicles will propel market growth. Kongsberg Maritime is the leading competitor in this fragmented market.

Execution of sustained organic growth in Canada, certain U.S. states, France, and the United Kingdom, derived from high quality pipeline of projects and growth path totaling 8 GW

Mobilicom’s corporate presentation and investment thesis can be viewed here: LINK